600 patients66,869 observations120 daysLIVE

Patient P-01868

Synthetic patientNBL-101 · Day 112 · 55–64 · M · baseline S14Open companion preview
Therapy response
Improving
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
90%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 48 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days
  • GI instability-20
  • Nutritional resilience+15
  • Inflammatory activity-12
  • Treatment adherence-6
  • Toxicity+2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    92%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 84% showed improvement
    • median effect visible after 8 days

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Inflammatory signalling 85
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • MicrobiomeBacteroides fragilis expansion
      • BloodInflammatory load index 53
      • WearableHRV 29 ms, trending down
    • Butyrate / short-chain fatty acid production 55
      • MicrobiomeButyrate capacity 24/100
      • Daily logFibre intake low in recent food logs
    • Mucosal barrier integrity 50
      • MicrobiomeAkkermansia low → thinner mucus layer
      • Daily logGI symptom score 51 and rising
    • Drug metabolism and exposure 20
      • BloodToxicity index 56
    • Autonomic recovery 20
      • WearableShort sleep window
    DNA
    Fictional pharmacogenomic panel
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Normal metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 1.9 · butyrate capacity 24/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisHigh
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    31 ms
    Sleep
    5.6 h
    Steps
    4,033
    Resting HR
    67 bpm
    Daily log: GI score 51, nutritional resilience 42, adherence 42.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0139653%S14GI-04worsened51
    P-0156448%S14ME-01improved39
    P-0175148%S14ME-01improved48
    P-0179748%S14NP-02no change43
    P-0145447%S14GI-04no change49
    P-0182647%S1042
    P-0160546%S14ME-01improved41
    P-0131145%S14ME-01improved49
    P-0159545%S14GI-04no change51
    P-0157644%S14NP-02no change49
    P-0173244%S14ME-01improved45
    P-0176044%S1442